Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma.

Xiang ZhouMaximilian J SteinhardtDenise GrathwohlKatharina MeckelKatharina NickelHans-Benno LeichtFranziska KrummenastHermann EinseleLeo RascheKlaus M Kortüm

Published in: Cancer medicine (2020)

Pom-PAD-Dara represents a promising multiagent regimen in heavily pretreated RRMM patients with high ORR and an acceptable safety profile.

Keyphrases

multiple myeloma
low dose
drug delivery
high dose
cancer therapy